Compare KPTI & VGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KPTI | VGI |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.6M | 89.0M |
| IPO Year | 2013 | N/A |
| Metric | KPTI | VGI |
|---|---|---|
| Price | $5.55 | $7.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $15.33 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 44.6K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.66% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $146,067,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $46.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $3.51 | $7.00 |
| 52 Week High | $10.99 | $8.09 |
| Indicator | KPTI | VGI |
|---|---|---|
| Relative Strength Index (RSI) | 30.46 | 31.31 |
| Support Level | $3.93 | N/A |
| Resistance Level | $6.96 | $7.97 |
| Average True Range (ATR) | 0.89 | 0.08 |
| MACD | -0.41 | -0.02 |
| Stochastic Oscillator | 13.61 | 23.75 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.